Literature DB >> 2069372

Pharmacokinetics of the penem CP-65,207 and its separate stereoisomers in humans.

G Foulds1, A K Knirsch, J D Lazar, T G Tensfelt, N Gerber.   

Abstract

CP-65,207 is a new broad-spectrum penem antimicrobial agent that is a 1:1 mixture of two stereoisomers. Five minutes after a 10-min intravenous infusion of 1 g of CP-65,207 to volunteers, mean concentrations in serum were 33 micrograms of the R isomer per ml and 29 micrograms of the S isomer per ml. Following rapid distribution, half-lives of the isomers were 53 and 55 min, respectively. Concentrations in urine exceeded 800 micrograms of each isomer per ml. Recovery of the S isomer in urine (46%) was much greater than recovery of the R isomer (26%). The serum kinetics of the S isomer (volume of distribution, 319 ml/kg; total clearance, 315 ml/min; elimination rate constant, 0.80 h-1 were similar when it was given alone and when it was contained in CP-65,207, demonstrating that the presence of the R isomer has little effect on the serum kinetics of the S isomer. However, when the S isomer was given alone, the urinary recovery of intact S isomer (36%) was substantially lower than that when it was given with the R isomer as CP-65,207 (57%). Administration of the S isomer alone did not produce the unpleasant sulfurous odor in urine that was observed following administration of CP-65,207. Oral doses of a prodrug, which contained 1 g of CP-65,207, produced peak concentrations in serum of 1.6 micrograms of the R isomer per ml and 1.8 micrograms of the S isomer per ml. Approximately 36% of the S-isomer component was absorbed, and 20% of this isomer was recovered in urine. A 1-g oral dose of the prodrug of the single S isomer provides concentrations in serum above 1.0 microgram/ml (the MIC for 90% of over 1,000 hospital pathogens) for 3.5 h, suggesting that the drug given orally will prove to be efficacious against many infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2069372      PMCID: PMC245076          DOI: 10.1128/AAC.35.4.665

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Meropenem pharmacokinetics and penetration into an inflammatory exudate.

Authors:  R Wise; M Logan; M Cooper; J P Ashby; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

2.  Evaluation of the in-vitro activity of Sch 29482.

Authors:  D Loebenberg; G H Miller; E L Moss; E Oden; R S Hare; M Chung; J A Waitz
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

3.  Oral absorption and tolerance in man, of a new penem antibiotic, Sch 29428.

Authors:  R Gural; C Lin; M Chung; E Oden; C Digiore
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

4.  Interspecies pharmacokinetic scaling of Sch 34343.

Authors:  M Chung; E Radwanski; D Loebenberg; C C Lin; E Oden; S Symchowicz; R P Gural; G H Miller
Journal:  J Antimicrob Chemother       Date:  1985-06       Impact factor: 5.790

5.  Pharmacokinetics of imipenem in healthy volunteers.

Authors:  S R Norrby; B Björnegård; F Ferber; K H Jones
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

6.  Multiple-dose pharmacokinetics of imipenem-cilastatin.

Authors:  G L Drusano; H C Standiford; C Bustamante; A Forrest; G Rivera; J Leslie; B Tatem; D Delaportas; R R MacGregor; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

Review 7.  Thienamycin: development of imipenen-cilastatin.

Authors:  F M Kahan; H Kropp; J G Sundelof; J Birnbaum
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

8.  Disposition of radiolabeled imipenem and cilastatin in normal human volunteers.

Authors:  S R Norrby; J D Rogers; F Ferber; K H Jones; A G Zacchei; L L Weidner; J L Demetriades; D A Gravallese; J Y Hsieh
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

9.  Synthesis and biological properties of sodium (5R, 6S, 8R)-6 alpha-hydroxyethyl-2-carbamoyloxymethyl-2-penem-3-carboxylate (FCE 22101) and its orally absorbed esters FCE 22553 and FCE 22891.

Authors:  G Franceschi; M Foglio; M Alpegiani; C Battistini; A Bedeschi; E Perrone; F Zarini; F Arcamone; C Della Bruna; A Sanfilippo
Journal:  J Antibiot (Tokyo)       Date:  1983-07       Impact factor: 2.649

10.  Structure-activity relationships in the 2-arylcarbapenem series: synthesis of 1-methyl-2-arylcarbapenems.

Authors:  R N Guthikonda; L D Cama; M Quesada; M F Woods; T N Salzmann; B G Christensen
Journal:  J Med Chem       Date:  1987-05       Impact factor: 7.446

View more
  2 in total

Review 1.  Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.

Authors:  George G Zhanel; Marianna Pozdirca; Alyssa R Golden; Courtney K Lawrence; Sheryl Zelenitsky; Liam Berry; Frank Schweizer; Denice Bay; Heather Adam; Michael A Zhanel; Philippe Lagacé-Wiens; Andrew Walkty; Neal Irfan; Kurt Naber; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2022-03-16       Impact factor: 9.546

Review 2.  Antibiotics in the clinical pipeline in October 2019.

Authors:  Mark S Butler; David L Paterson
Journal:  J Antibiot (Tokyo)       Date:  2020-03-10       Impact factor: 2.649

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.